Complete Report Title “Global Prenatal, Maternal & Carrier Diagnostic Market Analysis to 2021” is a comprehensive 390 page report strengthened with over 260 figures and tables available at RnRMarketResearch.com store for US $3900.

Pune, India-- (SBWire) -- 09/01/2016 --The GLOBAL PRENATAL, MATERNAL & SCREENING DIAGNOSTIC MARKET TO 2021 report has a detailed overview of 114 companies in the market with specifics pertaining to financial and business strategy, current products on the market and pipeline products.

The Global Prenatal and Maternal Diagnostic Test Market is assessed with respect to:

-Fetal Ultrasound
-Prenatal MRI Screening
-Carrier Screening Tests
-Maternal Serum Screening Tests
-Noninvasive Prenatal Tests (NIPTs) using cffDNA
-NIPTs by Product
-Prenatal Diagnostic Invasive Tests
-Newborn Screening for Genetic Diseases
-Newborn Screening Market by Technology
-Preimplantation Screening/Diagnosis (PGS/PGD)

Complete Report available@ http://www.rnrmarketresearch.com/global-prenatal-maternal-carrier-diagnostic-market-analysis-to-2021-market-report.html.

Objectives of this Report

The objective of this report is to provide an overview of the various technologies being employed for detecting genetic diseases in embryos, fetuses and newborns. The various chapters describe common pregnancy disorders, numerical chromosome disorders and structural chromosome disorders, single gene disorders inherited by fetuses, newborns and embryos.

SWOT and merger/acquisition analysis is also performed as is a comprehensive documentation of the legislation pertaining to newborn screening by geography and how clinical programs are implemented in developed and developing markets.

Emerging trends in associated markets are also analysed in order to give the reader a comprehensive overview of how prenatal and maternal diagnostic testing is affected by the following industries:
-Molecular Diagnostics Market
-Liquid Biopsy Market
-Personalized Medicine Diagnostics Market
-In vitro Diagnostics (IVD) Market

Prenatal tests (fetus, embryos and newborns) currently on the market analyze chromosomes, DNA, RNA, genes, and/or gene products to determine whether an abnormality is present that is causative of a specific disease. Since 2011, the launch of noninvasive prenatal tests (NIPTs) is revolutionizing the prenatal screening industry providing detection rates of >99% and false positive rates of <0.1%. These screening results are only indicative of the risk and not confirmative. To confirm positive results of NIPT screening tests, prenatal diagnostic tests such as amniocentesis and chorionic villus sampling (CVS) are performed. Prior to NIPTs, ultrasound and maternal serum tests were routinely used to screen fetusus for genetic abnormalities.

Globally, 50 countries have effective newborn genetic test programs, the implementation of which is in various stages. In the U.S., four million newborns are tested annually, with 3,000 found to have metabolic and genetic diseases. The purpose of newborn screening is to identify affected newborns quickly and provide them with treatment to prevent mental retardation, prolonged illness and death. The newborn genetic screening market is crowded with different technologies, the common being tandem mass spectrometry, pulse oximetry, enzyme-based assays, DNA assays and electrophoresis.

Request Sample of Report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=681504 OR Order a Copy of Report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=681504

Preimplantation genetic screening and preimplantation genetic diagnosis (PGS/PGD) are genetic tests performed in eight-celled embryos before implantation during in vitro fertilization (IVF) for the detection of genetic abnormalities and sex. These tests can detect and diagnose chromosomal rearrangements, X-linked diseases and help in reducing the incidence of spontaneous abortions, increase implantation rates, prevent trisomic offsprings and avoid the risk of transmitting single gene disorders. However, PGS and PGD results are not 100% accurate and after pregnancy, if required the diagnostic tests such as amniocentesis and CVS are to be performed to confirm the positive results of PGS/PGD. In the U.S. alone, more than 63,000 babies were born through IVF in 2013 and compared to 2012 data; it was an increase of 2,000 births.

Executive Summary

According to WHO, nearly 140 million babies are born every year, out of which 5 million die in the first month of life, mostly in developing countries. For example, in India, about 5% to 15% of sick newborns have a metabolic disorder. This emphasizes the need for newborn screening for preventing disability and death by early intervention, follow-up and counselling.

Globally, the use of maternal serum marker screening and ultrasound imaging for the detection of chromosome aneuploidies and other birth defects constitute a routine part of prenatal care in the first and/or second trimesters. Yet, both of these techniques have the disadvantages of high false positive rates, varying from 2% to 7%. If the results of these tests show that a fetus is at increased risk of aneuploidy, invasive approaches such as chorionic villus sampling (CVS) or amniocentesis are recommended for diagnosis.

Product Description

Fetal Ultrasound Screening Market

Today, ultrasound is used on average five times per pregnancy before delivery. The fetal ultrasound screening market generated revenues of about $x million in 2014 with the potential to earn $x million in 2021, growing at a CAGR of x%. Fetal MRI prenatal screening is performed rarely, only when the ultrasound screening provides an ambiguous result and to detect suspected central nervous system (CNS) disorders in the fetus during the second trimester. The fetal MRI segment had generated estimated revenue of $x million in 2014 with a potential to earn $x million in 2021.

Maternal Serum Testing Market

The global maternal serum test market was worth $x million in 2014 and is forecast to grow and reach $x million by 2021. The market consists of test methods for:
-Pregnancy-associated plasma protein (PAPP-A)
-Alpha-fetoprotein (AFP)
-Human chorionic gonadotropin (hCG)
-Estriol
-Inhibin-A

Had it not been for the launch of noninvasive prenatal tests (NIPTs) in 2011, this market would have fared much better.

Noninvasive Prenatal Test Market

Noninvasive prenatal tests (NIPTs) are the future of prenatal screening and have shown signs of surpassing the traditional maternal serum test revenues by earning about $x million in 2014. With a CAGR of x%, this market is forecast to reach $x million in 2021.

Newborn Screening Market

Newborn screening is an accepted national health policy in about 52 countries. It is a well-entrenched routine of newborn care in the U.S., U.K., Japan, Australia and most western European countries for the last three decades. In the Asian continent, China, Philippines and Thailand have developed admirable newborn screening programs in a relatively short period of time. Mass spectrometry has become the standard technique for newborn screening. Using this technique, medical technologists are capable of screening as many as 30 metabolic disorders from a single sample of blood. The global market for newborn screening has been valued at $x million in 2014 and it will be worth about $x million by 2021.

Preimplantation Genetic Diagnosis Market

Preimplantation genetic diagnosis (PGD) has been in practice for more than twenty years in about 60 countries globally. PGD testing is performed to identify genetic defects in embryos. The tests are usually performed in cases of a known genetic defect, in late age pregnancy, or in patients with a history of repeated miscarriages. PCR, FISH, CGH, and SNP analysis are some of the most common techniques used, and PCR is the most widely used technology. The global market for PGD was worth about $x million in 2014 and this has been predicted to enlarge and reach $x million in 2021.

Inquire for Discount on Report @ http://www.rnrmarketresearch.com/contacts/discount?rname=681504.

Key Questions Answered in This Report

-What are the major prenatal pregnancy complications?
-What are the major genetic diseases detected in fetuses?
-What are the appropriate technologies for the detection of aneuploidies, microdeletions, duplications, copy number variations/alterations and translocations?
-How far is genetic counseling important in educating pregnant women and healthcare professionals?
-What is the impact of recent advances in clinical genomics on genetic counseling?
-What different noninvasive and invasive prenatal screening tests are performed during a pregnancy?
-What are the detection rates, true positive rates and true negative rates for NIPTs?
-Currently, in which countries are NIPTs available?
-What is the cost of NIPTs region-wise?
-What is the uptake of conventional maternal serum tests, NIPTs and invasive diagnostic tests in the S.?
-What is the average cost of maternal serum screening, NIPTs, fetal ultrasound screening and invasive diagnostic tests in the S.? And more..

Table of Content

Introduction
Prenatal Pregnancy Complications: An Overview
Types of Genetic Diseases in Fetuses: An Overview
Genetic Counselling: An Overview
Prenatal Screening for Genetic Diseases: An Overview
Newborn Screening
Preimplantation Genetic Screening & Genetic Diagnosis (PGS/PGD)
Pregnancy, Prenatal, Newborn and PGD-Related Technologies: An Overview
Prenatal Screening and Diagnostics: Market Overview
Other Genetic Testing-Related Markets
Acquisition Activities in Prenatal Screening Industry
Company Profiles
Appendix

About RnRMarketResearch.com
RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.